Celecoxib-induced maculopapular exanthema with a positive patch test
Main Article Content
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are among therapeutics most frequently causing pseudoallergic and allergic cutaneous adverse reactions. Celecoxib represents a class of coxibs that selectively inhibit cyclooxygenase 2 (COX-2). This medication has been associated with several severe drug-induced skin reactions and maculopapular exanthemas. We present a case of maculopapular exanthemas diagnosed by patch testing. A 39-year-old woman with no history of allergies presented to our outpatient clinic with a maculopapular rash on her trunk after 9 days of taking celecoxib and other medications. She was treated with methylprednisolone and antihistamines. The symptoms cleared after 2 weeks of discontinuing Celecoxib. Patch testing was performed on her back four weeks after the hypersensitivity reaction. Patch testing was performed with celecoxib diluted at 5% and 10% concentrations in petrolatum to avoid false-positive results due to irritation. Celecoxib patches at both concentrations gave positive results after 48 and 96 hours. Therefore, appropriate drug test concentrations are important in identifying suspected drug allergens.
Article Details
Keywords
Celecoxib allergy, drug allergy, maculopapular exanthema drug NSAIDS, patch test
References
2. Shin HT, Park SW, Lee KT, et al. A Case of Celecoxib Induced Acute Generalized Exanthematous Pustulosis. Ann Dermatol. 2011; 23(Suppl 3): S380. doi:10.5021/ad.2011.23.S3.S380.
3. Alonso JCM, Ortega JD, Gonzalo MJF. Cutaneous reaction to oral celecoxib with positive patch test. Contact Dermatitis. 2004; 50(1): 48-49. doi:10.1111/j.0105-1873.2004.00271i.x.
4. Berger P, Dwyer D, Corallo CE. Toxic Epidermal Necrolysis After Celecoxib Therapy. Pharmacotherapy. 2002; 22(9): 1193-1195. doi:10.1592/phco.22.13.1193.33513.
5. Lee S, Lee D, Kim D, Kim M, Lee U, Hahm J. Acute generalized exanthematous pustulosis induced by celecoxib. J Cutan Pathol. 2016; 43(1): 80-81. doi:10.1111/cup.12604.
6. Yazici AC, Baz K, Ikizoglu G, Kokturk A, Uzumlu H, Tataroglu C. Celecoxib-induced photoallergic drug eruption. Int J Dermatology. 2004; 43(6): 459-461. doi:10.1111/j.1365-4632.2004.02149.x.
7. Pakdeethai J, Ho SA, Aw D, Tan KB. Acute generalized exanthematous pustulosis-like, folliculitic drug reaction pattern caused by celecoxib: AGEP-like, folliculitic ADR caused by celecoxib. Dermatologic Therapy. 2011; 24(5): 505-507. doi:10.1111/j.1529-8019.2012.01474.x.
8. Ding R, Cheo FF, Lee HY. Celecoxib and Bullous Symmetrical Drug-Related Intertriginous and Flexural Exanthem (SDRIFE). The Journal of Allergy and Clinical Immunology: In Practice. 2023; 11(2): 629-631. doi:10.1016/j.jaip.2022.11.028.
9. Johansen JD, Aalto-Korte K, Agner T, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing – recommendations on best practice. Contact Dermatitis. 2015; 73(4): 195-221. doi:10.1111/cod.12432.
10. Fonacier L. A Practical Guide to Patch Testing. The Journal of Allergy and Clinical Immunology: In Practice. 2015; 3(5): 669-675. doi:10.1016/j.jaip.2015.05.001.
11. Li L, Laidlaw T. Cross-reactivity and tolerability of celecoxib in adult patients with NSAID hypersensitivity. The Journal of Allergy and Clinical Immunology: In Practice. 2019; 7(8): 2891-2893.e4. doi:10.1016/j.jaip.2019.04.042
12. Martínez Antón MD, Galán Gimeno C, Sánchez De Vicente J, Jáuregui Presa I, Gamboa Setién PM. Etoricoxib-induced fixed drug eruption: Report of seven cases. Contact Dermatitis. 2021; 84(3): 192-195. doi:10.1111/cod.13659
13. Gómez De La Fuente E, Pampín Franco A, Caro Gutiérrez D, López Estebaranz JL. Exantema fijo medicamentoso por etoricoxib con tolerancia a celecoxib. Utilidad de las pruebas epicutáneas. Actas Dermo-Sifiliográficas. 2014; 105(3): 314-315. doi:10.1016/j.ad.2013.04.008.
14. Ponce V, Muñoz-Bellido F, Moreno E, Laffond E, González A, Dávila I. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib. Contact Dermatitis. 2012; 66(2): 107-108. doi:10.1111/j.1600-0536.2011.01982.x.
15. Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: A 2022 practice parameter update. Journal of Allergy and Clinical Immunology. 2022; 150(6): 1333-1393. doi:10.1016/j.jaci.2022.08.028.
16. Copaescu AM, Ben-Shoshan M, Trubiano JA. Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions. Frontiers in Medicine. 2022; 9:923991. doi:10.3389/fmed.2022.923991.
17. Wiholm BE. Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database. Curr Med Res Opin. 2001; 17(3): 210-216. doi:10.1185/0300799039117065.
18. Muntingh GL. Do some of the newer COX-2 inhibitors cross-react with sulfonamide antibiotics? An overview. SA Orthopaedic Journal. 2011; 10(1): 73-76. Accessed October 20, 2024.
19. Knowles S, Shapiro L, Shear NH: Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of ‘sulfa’ allergy. Drug Saf .2001; 24: 239– 247.
20. Ernst EJ, Egge JA. Celecoxib-Induced Erythema Multiforme with Glyburide Cross-Reactivity. Pharmacotherapy. 2002; 22(5): 637-640. doi:10.1592/phco.22.8.637.33200.
21. Kleinhans M, Linzbach L, Zedlitz S, Kaufmann R, Boehncke W - H. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis. 2002; 47(2): 100-102. doi:10.1034/j.1600-0536.2002.470208.x.
22. Arakawa Y, Nakai N, Katoh N. Celecoxib-induced erythema multiforme-type drug eruption with a positive patch test: Letters to the Editor. The Journal of Dermatology. 2011; 38(12): 1185-1188. doi:10.1111/j.1346-8138.2010.01182.x.
23. Ammar H, Ben Fredj N, Ben Romdhane H, et al. Cross-reactivity between nonsteroidal anti-inflammatory drugs in fixed drug eruption: Two unusual cases and a literature review. Br J Clin Pharmacol. 2023; 89(2): 561-573. doi:10.1111/bcp.15565.